$MCRB
Seres Therapeutics, Inc.

2023 Q4 Form 10-Q Financial Statement

#000095017023057805 Filed on November 02, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $64.00K $310.0K
YoY Change -93.44% -91.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $17.23M $20.00M
YoY Change -23.08% 8.79%
% of Gross Profit
Research & Development $26.85M $28.25M
YoY Change -41.92% -34.47%
% of Gross Profit
Depreciation & Amortization $1.632M $1.684M
YoY Change 0.31% -3.61%
% of Gross Profit
Operating Expenses $39.59M $47.72M
YoY Change -42.86% -23.71%
Operating Profit -$47.41M
YoY Change -19.78%
Interest Expense -$2.058M -$1.400M
YoY Change 341.63% 62.41%
% of Operating Profit
Other Income/Expense, Net $336.0K -$441.0K
YoY Change -1560.87% -50.73%
Pretax Income -$41.25M -$47.90M
YoY Change -40.04% -20.17%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$41.25M -$47.85M
YoY Change -40.04% -20.25%
Net Earnings / Revenue -64450.0% -15436.77%
Basic Earnings Per Share -$0.37
Diluted Earnings Per Share -$0.32 -$0.37
COMMON SHARES
Basic Shares Outstanding 129.3M 128.2M
Diluted Shares Outstanding 128.3M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $128.0M $169.9M
YoY Change -29.43% -27.08%
Cash & Equivalents $128.0M $169.9M
Short-Term Investments $0.00 $0.00
Other Short-Term Assets $9.124M $9.100M
YoY Change -32.03% -37.28%
Inventory $29.65M $18.53M
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $175.4M $214.4M
YoY Change -9.94% -13.38%
LONG-TERM ASSETS
Property, Plant & Equipment $22.46M $23.57M
YoY Change -2.3% 20.95%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $41.35M $12.05M
YoY Change 295.16% 4.42%
Total Long-Term Assets $183.2M $153.3M
YoY Change 18.94% 138.22%
TOTAL ASSETS
Total Short-Term Assets $175.4M $214.4M
Total Long-Term Assets $183.2M $153.3M
Total Assets $358.6M $367.7M
YoY Change 2.81% 17.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.641M $8.958M
YoY Change -79.12% -14.27%
Accrued Expenses $23.14M $19.80M
YoY Change 26.39% 9.31%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $98.66M $79.23M
YoY Change 15.26% -3.17%
LONG-TERM LIABILITIES
Long-Term Debt $101.5M $101.1M
YoY Change 100.72% 98.79%
Other Long-Term Liabilities $1.628M $1.579M
YoY Change 12.9% 64.31%
Total Long-Term Liabilities $1.628M $1.579M
YoY Change 12.9% 64.31%
TOTAL LIABILITIES
Total Short-Term Liabilities $98.66M $79.23M
Total Long-Term Liabilities $1.628M $1.579M
Total Liabilities $403.5M $382.8M
YoY Change 19.37% 56.71%
SHAREHOLDERS EQUITY
Retained Earnings -$978.2M -$937.0M
YoY Change 13.15% 17.75%
Common Stock $933.4M $921.9M
YoY Change 6.63% 6.77%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$44.86M -$15.12M
YoY Change
Total Liabilities & Shareholders Equity $358.6M $367.7M
YoY Change 2.81% 17.9%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$41.25M -$47.85M
YoY Change -40.04% -20.25%
Depreciation, Depletion And Amortization $1.632M $1.684M
YoY Change 0.31% -3.61%
Cash From Operating Activities -$47.50M -$59.30M
YoY Change -10.2% -0.47%
INVESTING ACTIVITIES
Capital Expenditures $877.0K $1.800M
YoY Change -74.66% -244.35%
Acquisitions
YoY Change
Other Investing Activities -$43.00K $0.00
YoY Change -100.46% -100.0%
Cash From Investing Activities -$877.0K -$1.800M
YoY Change -114.8% -104.49%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 6.429M 1.500M
YoY Change 39.85% -98.47%
NET CHANGE
Cash From Operating Activities -47.50M -59.30M
Cash From Investing Activities -877.0K -1.800M
Cash From Financing Activities 6.429M 1.500M
Net Change In Cash -41.95M -59.60M
YoY Change -1.0% -175.85%
FREE CASH FLOW
Cash From Operating Activities -$47.50M -$59.30M
Capital Expenditures $877.0K $1.800M
Free Cash Flow -$48.38M -$61.10M
YoY Change -14.16% 4.74%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001609809
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2023#LicenseAndServiceMember
CY2022Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2023#LicenseAndServiceMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2023#LicenseAndServiceMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2023#LicenseAndServiceMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37465
dei Entity Registrant Name
EntityRegistrantName
Seres Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-4326290
dei Entity Address Address Line1
EntityAddressAddressLine1
200 Sidney Street - 4th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02139
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
945-9626
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001
dei Trading Symbol
TradingSymbol
MCRB
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
129257199
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
169912000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
163030000
CY2023Q3 us-gaap Short Term Investments
ShortTermInvestments
0
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
18311000
CY2023Q3 mcrb Collaboration Receivable Related Party
CollaborationReceivableRelatedParty
16857000
CY2022Q4 mcrb Collaboration Receivable Related Party
CollaborationReceivableRelatedParty
0
CY2023Q3 us-gaap Inventory Net
InventoryNet
18525000
CY2022Q4 us-gaap Inventory Net
InventoryNet
0
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9100000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
13423000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
214394000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
194764000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
23566000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
22985000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
108105000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
110984000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
8185000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
8185000
CY2023Q3 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
1401000
CY2022Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
1401000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
12048000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
10465000
CY2023Q3 us-gaap Assets
Assets
367699000
CY2022Q4 us-gaap Assets
Assets
348784000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
8958000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
17440000
CY2023Q3 mcrb Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
54158000
CY2022Q4 mcrb Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
59840000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6280000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3601000
CY2023Q3 us-gaap Notes Payable Current
NotesPayableCurrent
0
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
456000
CY2023Q3 us-gaap Deferred Income
DeferredIncome
9465000
CY2022Q4 us-gaap Deferred Income
DeferredIncome
0
CY2023Q3 mcrb Contract With Customer Liability Current Related Party
ContractWithCustomerLiabilityCurrentRelatedParty
364000
CY2022Q4 mcrb Contract With Customer Liability Current Related Party
ContractWithCustomerLiabilityCurrentRelatedParty
4259000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
79225000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
85596000
CY2023Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
101135000
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
50591000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
104863000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
107942000
CY2023Q3 mcrb Contract With Customer Liability Noncurrent Related Party
ContractWithCustomerLiabilityNoncurrentRelatedParty
95064000
CY2022Q4 mcrb Contract With Customer Liability Noncurrent Related Party
ContractWithCustomerLiabilityNoncurrentRelatedParty
92430000
CY2023Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
956000
CY2022Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
0
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1579000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1442000
CY2023Q3 us-gaap Liabilities
Liabilities
382822000
CY2022Q4 us-gaap Liabilities
Liabilities
338001000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
240000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
128630689
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
128630689
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
125222273
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
125222273
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
129000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
125000
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
921735000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
875181000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-12000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-936987000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-864511000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-15123000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
10783000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
367699000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
348784000
CY2023Q3 mcrb Collaboration Revenue From Related Party
CollaborationRevenueFromRelatedParty
310000
CY2022Q3 mcrb Collaboration Revenue From Related Party
CollaborationRevenueFromRelatedParty
3444000
mcrb Collaboration Revenue From Related Party
CollaborationRevenueFromRelatedParty
126261000
mcrb Collaboration Revenue From Related Party
CollaborationRevenueFromRelatedParty
6153000
CY2023Q3 us-gaap Revenues
Revenues
310000
CY2022Q3 us-gaap Revenues
Revenues
3444000
us-gaap Revenues
Revenues
126261000
us-gaap Revenues
Revenues
6153000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28253000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
43116000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
119014000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
126700000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19989000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18384000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
70510000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
57290000
CY2023Q3 mcrb Profit Loss From Research Agreements Related Party
ProfitLossFromResearchAgreementsRelatedParty
-519000
CY2022Q3 mcrb Profit Loss From Research Agreements Related Party
ProfitLossFromResearchAgreementsRelatedParty
1051000
mcrb Profit Loss From Research Agreements Related Party
ProfitLossFromResearchAgreementsRelatedParty
5194000
mcrb Profit Loss From Research Agreements Related Party
ProfitLossFromResearchAgreementsRelatedParty
346000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
47723000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
62551000
us-gaap Operating Expenses
OperatingExpenses
194718000
us-gaap Operating Expenses
OperatingExpenses
184336000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-47413000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-59107000
us-gaap Operating Income Loss
OperatingIncomeLoss
-68457000
us-gaap Operating Income Loss
OperatingIncomeLoss
-178183000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
2572000
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
865000
us-gaap Investment Income Interest
InvestmentIncomeInterest
5330000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1644000
CY2023Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
4012000
CY2022Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
1727000
us-gaap Interest Expense Debt
InterestExpenseDebt
9147000
us-gaap Interest Expense Debt
InterestExpenseDebt
4140000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
999000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-33000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-202000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-682000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-441000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-895000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4019000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3178000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-47854000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-60002000
us-gaap Net Income Loss
NetIncomeLoss
-72476000
us-gaap Net Income Loss
NetIncomeLoss
-181361000
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.37
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.37
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
96721000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
429000
CY2022Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
877000
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.49
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.49
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.57
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.57
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.77
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.77
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
128289871
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
128289871
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
122527275
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
122527275
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
127297667
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
127297667
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
102380700
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
102380700
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
140000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
10000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-56000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
2000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
138000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
12000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-58000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-47853000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-59864000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-72464000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-181419000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
131507000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
257000
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
892000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5079000
CY2022Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-155000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-56624000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
80956000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
130000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6748000
CY2022Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-41000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-64735000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
23058000
CY2022Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3279000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6364000
CY2022Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
138000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-60002000
mcrb Increase Decrease In Defered Income Related Party
IncreaseDecreaseInDeferedIncomeRelatedParty
0
mcrb Increase Decrease In Contract With Customer Liability Related Party
IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty
-1261000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
67585000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
10783000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
188000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1229000
CY2023Q1 mcrb Stock Issued During Period Value At Market Equity Offerings
StockIssuedDuringPeriodValueAtMarketEquityOfferings
4239000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6850000
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
14000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-71174000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-47871000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
168000
CY2023Q2 mcrb Stock Issued During Period Value At Market Equity Offerings
StockIssuedDuringPeriodValueAtMarketEquityOfferings
7491000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
2785000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13492000
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-3000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
46552000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
22614000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
521000
CY2023Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
922000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8673000
CY2023Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
1000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-47854000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-15123000
us-gaap Net Income Loss
NetIncomeLoss
-72476000
us-gaap Net Income Loss
NetIncomeLoss
-181361000
us-gaap Share Based Compensation
ShareBasedCompensation
29015000
us-gaap Share Based Compensation
ShareBasedCompensation
18191000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4611000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5002000
mcrb Non Cash Operating Lease Cost
NonCashOperatingLeaseCost
6450000
mcrb Non Cash Operating Lease Cost
NonCashOperatingLeaseCost
3558000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
236000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-676000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
730000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
553000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1625000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1144000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
mcrb Collaboration Profit Loss Related To Pre Launch Activities
CollaborationProfitLossRelatedToPreLaunchActivities
-5158000
mcrb Collaboration Profit Loss Related To Pre Launch Activities
CollaborationProfitLossRelatedToPreLaunchActivities
-346000
mcrb Increase Decrease In Prepaid Expenses And Other Current And Long Term Assets
IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAndLongTermAssets
2504000
mcrb Increase Decrease In Prepaid Expenses And Other Current And Long Term Assets
IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAndLongTermAssets
-12899000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
16857000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
0
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
18525000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0
mcrb Increase Decrease In Defered Income Related Party
IncreaseDecreaseInDeferedIncomeRelatedParty
9465000
mcrb Increase Decrease In Contract With Customer Liability Related Party
IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty
-6153000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-6539000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3250000
mcrb Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1635000
mcrb Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-3520000
mcrb Increase Decrease In Accrued Expenses And Other Current And Long Term Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentAndLongTermLiabilities
-10740000
mcrb Increase Decrease In Accrued Expenses And Other Current And Long Term Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentAndLongTermLiabilities
2933000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-69855000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-175924000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7098000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6360000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
4426000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
36138000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
22983000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
119000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
11459000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
76502000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
877000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
816000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
100000000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3279000
mcrb Proceeds From Issuance Of Common Stock From At The Market Equity Offering
ProceedsFromIssuanceOfCommonStockFromAtTheMarketEquityOffering
11730000
mcrb Proceeds From Issuance Of Common Stock From At The Market Equity Offering
ProceedsFromIssuanceOfCommonStockFromAtTheMarketEquityOffering
0
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
2151000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1769000
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
103378000
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
27606000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
52860000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1907000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
65276000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
125005000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
6880000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
25583000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-2000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
171215000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
188002000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
178097000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
213583000
us-gaap Interest Paid Net
InterestPaidNet
8966000
us-gaap Interest Paid Net
InterestPaidNet
3282000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
370000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1061000
mcrb Prepaid Rent Reclassified To Right Of Use Assets
PrepaidRentReclassifiedToRightOfUseAssets
2336000
mcrb Prepaid Rent Reclassified To Right Of Use Assets
PrepaidRentReclassifiedToRightOfUseAssets
4962000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1235000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4370000
mcrb Non Financial Liabilities For Warrants Recognised
NonFinancialLiabilitiesForWarrantsRecognised
2100000
mcrb Non Financial Liabilities For Warrants Recognised
NonFinancialLiabilitiesForWarrantsRecognised
0
mcrb Warrants Issued Related To Term Loan And Recorded As Debt Discount
WarrantsIssuedRelatedToTermLoanAndRecordedAsDebtDiscount
2785000
mcrb Warrants Issued Related To Term Loan And Recorded As Debt Discount
WarrantsIssuedRelatedToTermLoanAndRecordedAsDebtDiscount
0
mcrb Accrued Expenses And Other Current And Long Term Liabilities Related Party Amounts
AccruedExpensesAndOtherCurrentAndLongTermLiabilitiesRelatedPartyAmounts
-227000
mcrb Accrued Expenses And Other Current And Long Term Liabilities Related Party Amounts
AccruedExpensesAndOtherCurrentAndLongTermLiabilitiesRelatedPartyAmounts
-2429000
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
mcrb Entity Incorporation Month And Year Of Incorporation
EntityIncorporationMonthAndYearOfIncorporation
2010-10
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-936987000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
169912000
us-gaap Net Income Loss
NetIncomeLoss
-72476000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-69855000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. In the unaudited condensed consolidated financial statements, the Company uses estimates and assumptions related to revenue recognition and the accrual of research and development expenses. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from those estimates.</span></p>
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
8185000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
8185000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
169912000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
163030000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
8185000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
8185000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
178097000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
171215000
CY2023Q3 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
1401000
CY2022Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
1401000
CY2022Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
0
CY2022Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
0
CY2023Q3 mcrb Fair Value Assets Level1 To Level2 Transfers Amount1
FairValueAssetsLevel1ToLevel2TransfersAmount1
0
CY2023Q3 mcrb Fair Value Assets Level2 To Level1 Transfers Amount1
FairValueAssetsLevel2ToLevel1TransfersAmount1
0
CY2023Q3 mcrb Fair Value Assets Level1 To Level3 Transfers Amount
FairValueAssetsLevel1ToLevel3TransfersAmount
0
CY2023Q3 mcrb Fair Value Assets Level3 To Level1 Transfers Amount
FairValueAssetsLevel3ToLevel1TransfersAmount
0
CY2023Q3 mcrb Fair Value Assets Level2 To Level3 Transfers Amount
FairValueAssetsLevel2ToLevel3TransfersAmount
30000
CY2023Q3 mcrb Fair Value Assets Level3 To Level2 Transfers Amount
FairValueAssetsLevel3ToLevel2TransfersAmount
30000
CY2022Q3 mcrb Fair Value Assets Level1 To Level2 Transfers Amount1
FairValueAssetsLevel1ToLevel2TransfersAmount1
30000
CY2022Q3 mcrb Fair Value Assets Level1 To Level3 Transfers Amount
FairValueAssetsLevel1ToLevel3TransfersAmount
30000
CY2022Q3 mcrb Fair Value Assets Level3 To Level1 Transfers Amount
FairValueAssetsLevel3ToLevel1TransfersAmount
2023000
CY2022Q3 mcrb Fair Value Assets Level2 To Level3 Transfers Amount
FairValueAssetsLevel2ToLevel3TransfersAmount
2023000
CY2022Q3 mcrb Fair Value Assets Level3 To Level2 Transfers Amount
FairValueAssetsLevel3ToLevel2TransfersAmount
2023000
CY2022Q3 mcrb Fair Value Assets Level2 To Level1 Transfers Amount1
FairValueAssetsLevel2ToLevel1TransfersAmount1
2023000
CY2023Q3 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
1401000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
18321000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
13000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
18311000
CY2022Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
1401000
mcrb Cash Equivalents Original Maturity Maximum Period
CashEquivalentsOriginalMaturityMaximumPeriod
P90D
CY2022 mcrb Cash Equivalents Original Maturity Maximum Period
CashEquivalentsOriginalMaturityMaximumPeriod
P90D
CY2023Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
3532000
CY2023Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
14993000
CY2023Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
0
CY2023Q3 us-gaap Inventory Net
InventoryNet
18525000
CY2022Q4 us-gaap Inventory Net
InventoryNet
0
CY2023Q3 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
0
us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
26794000
CY2023Q3 us-gaap Inventory Write Down
InventoryWriteDown
0
us-gaap Inventory Write Down
InventoryWriteDown
0
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
73217000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
68025000
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
49651000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
45040000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
23566000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
22985000
CY2023Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1684000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4611000
CY2022Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1747000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5002000
CY2023Q3 mcrb Accrued Clinical And Development Costs Current
AccruedClinicalAndDevelopmentCostsCurrent
1491000
CY2022Q4 mcrb Accrued Clinical And Development Costs Current
AccruedClinicalAndDevelopmentCostsCurrent
6717000
CY2023Q3 mcrb Manufacturing And Quality Costs
ManufacturingAndQualityCosts
1719000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
13479000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
14709000
CY2023Q3 mcrb Transaction Price Allocated Under Collaborative Arrangement
TransactionPriceAllocatedUnderCollaborativeArrangement
34543000
CY2022Q4 mcrb Transaction Price Allocated Under Collaborative Arrangement
TransactionPriceAllocatedUnderCollaborativeArrangement
34770000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2926000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3644000
CY2023Q3 mcrb Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
54158000
CY2022Q4 mcrb Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
59840000
us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
Certain leases include one or more options to renew, exercisable at the Company’s sole discretion, with renewal terms that can extend the lease from approximately one year to ten years.
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2022Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P10Y
CY2022Q2 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2022Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
1937000
us-gaap Operating Lease Payments
OperatingLeasePayments
5382000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
11608000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2507053
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
260640
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
816324
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
108105000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
110984000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6280000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3601000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
104863000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
107942000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
111143000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
111543000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
5544000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1785000
us-gaap Operating Lease Cost
OperatingLeaseCost
16496000
us-gaap Operating Lease Cost
OperatingLeaseCost
5405000
CY2023Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
362000
CY2022Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
326000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
1102000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
1035000
CY2023Q3 us-gaap Variable Lease Cost
VariableLeaseCost
1699000
CY2022Q3 us-gaap Variable Lease Cost
VariableLeaseCost
1135000
us-gaap Variable Lease Cost
VariableLeaseCost
5643000
us-gaap Variable Lease Cost
VariableLeaseCost
3437000
CY2023Q3 us-gaap Lease Cost
LeaseCost
7605000
CY2022Q3 us-gaap Lease Cost
LeaseCost
3246000
us-gaap Lease Cost
LeaseCost
23241000
us-gaap Lease Cost
LeaseCost
9877000
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
4399000
us-gaap Operating Lease Payments
OperatingLeasePayments
11687000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
4221000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
19437000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
21555000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
22155000
CY2023Q3 mcrb Lessee Operating Lease Liability To Be Paid After Year Three
LesseeOperatingLeaseLiabilityToBePaidAfterYearThree
111164000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
178532000
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
67389000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
111143000
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y2M23D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.13
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y7M20D
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.10
CY2023Q2 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
50446000
CY2023Q2 us-gaap Debt Instrument Convertible Threshold Trading Days
DebtInstrumentConvertibleThresholdTradingDays
30
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
0
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
0
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
24750000
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
33000000
CY2023Q3 mcrb Long Term Debt Maturity After Year Four
LongTermDebtMaturityAfterYearFour
52250000
CY2023Q3 us-gaap Long Term Debt
LongTermDebt
110000000
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
240000000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
14940034
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.03
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y3M
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
16370123
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.47
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y9M10D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
135000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
10000136
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
10.05
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y8M1D
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.14
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.52
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.07
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.53
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8673000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6364000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
29015000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
18191000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-47854000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-60002000
us-gaap Net Income Loss
NetIncomeLoss
-72476000
us-gaap Net Income Loss
NetIncomeLoss
-181361000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
128289871
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
128289871
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
122527275
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
122527275
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
127297667
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
127297667
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
102380700
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
102380700
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.37
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.37
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.49
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.49
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.57
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.57
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.77
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.77
CY2016Q1 mcrb Collaborative Arrangement Upfront License Fee Received
CollaborativeArrangementUpfrontLicenseFeeReceived
120000000
CY2023Q3 mcrb Contract With Customer Liability Revenue Recognized With Related Party
ContractWithCustomerLiabilityRevenueRecognizedWithRelatedParty
310000
CY2022Q3 mcrb Contract With Customer Liability Revenue Recognized With Related Party
ContractWithCustomerLiabilityRevenueRecognizedWithRelatedParty
3444000
mcrb Contract With Customer Liability Revenue Recognized With Related Party
ContractWithCustomerLiabilityRevenueRecognizedWithRelatedParty
-714000
mcrb Contract With Customer Liability Revenue Recognized With Related Party
ContractWithCustomerLiabilityRevenueRecognizedWithRelatedParty
6153000
CY2023Q3 mcrb Collaboration Profit Loss Related To Pre Launch Activities
CollaborationProfitLossRelatedToPreLaunchActivities
-313000
CY2023Q3 mcrb Share Of Related Party Net Loss
ShareOfRelatedPartyNetLoss
-6463000
CY2022Q3 mcrb Share Of Related Party Net Loss
ShareOfRelatedPartyNetLoss
0
mcrb Share Of Related Party Net Loss
ShareOfRelatedPartyNetLoss
-8604000
mcrb Share Of Related Party Net Loss
ShareOfRelatedPartyNetLoss
0
CY2023Q3 mcrb Profit On Transfer Of Related Party Inventory
ProfitOnTransferOfRelatedPartyInventory
7295000
CY2022Q3 mcrb Profit On Transfer Of Related Party Inventory
ProfitOnTransferOfRelatedPartyInventory
0
mcrb Profit On Transfer Of Related Party Inventory
ProfitOnTransferOfRelatedPartyInventory
8568000
mcrb Profit On Transfer Of Related Party Inventory
ProfitOnTransferOfRelatedPartyInventory
0
CY2023Q3 mcrb Collaboration Profit Loss Related To Pre Launch Activities
CollaborationProfitLossRelatedToPreLaunchActivities
-313000
CY2022Q3 mcrb Collaboration Profit Loss Related To Pre Launch Activities
CollaborationProfitLossRelatedToPreLaunchActivities
-1051000
mcrb Collaboration Profit Loss Related To Pre Launch Activities
CollaborationProfitLossRelatedToPreLaunchActivities
-5158000
mcrb Collaboration Profit Loss Related To Pre Launch Activities
CollaborationProfitLossRelatedToPreLaunchActivities
-346000
CY2023Q3 mcrb Profit Loss From Research Agreement Related Party
ProfitLossFromResearchAgreementRelatedParty
519000
CY2022Q3 mcrb Profit Loss From Research Agreement Related Party
ProfitLossFromResearchAgreementRelatedParty
-1051000
mcrb Profit Loss From Research Agreement Related Party
ProfitLossFromResearchAgreementRelatedParty
-5194000
mcrb Profit Loss From Research Agreement Related Party
ProfitLossFromResearchAgreementRelatedParty
-346000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q3 us-gaap Deferred Income
DeferredIncome
9465000
CY2022Q4 us-gaap Deferred Income
DeferredIncome
0
CY2023Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
mcrb-20230930_cal.xml Edgar Link unprocessable
0000950170-23-057805-index-headers.html Edgar Link pending
0000950170-23-057805-index.html Edgar Link pending
0000950170-23-057805.txt Edgar Link pending
0000950170-23-057805-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
mcrb-20230930.htm Edgar Link pending
mcrb-20230930.xsd Edgar Link pending
mcrb-ex31_1.htm Edgar Link pending
mcrb-ex31_2.htm Edgar Link pending
mcrb-ex32_1.htm Edgar Link pending
mcrb-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
mcrb-20230930_def.xml Edgar Link unprocessable
mcrb-20230930_pre.xml Edgar Link unprocessable
mcrb-20230930_lab.xml Edgar Link unprocessable
mcrb-20230930_htm.xml Edgar Link completed
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable